


# UPDATE ON LIRAGLUTIDE (SAXENDA®) FOR WEIGHT MANAGEMENT



The HSE introduced a managed access protocol (MAP) for liraglutide (Saxenda®) in January 2023. The aim of the MAP is to provide patients with an initial body mass index (BMI) greater than or equal to  $35 \text{ kg/m}^2$ , with prediabetes and high-risk for cardiovascular disease, with access to liraglutide (Saxenda®) for weight management.

Liraglutide (Saxenda®) is a glucagon-like peptide-1 analogue, and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients.

By October 2023, over 1,400 patients were accessing treatment with liraglutide (Saxenda®) under the Community Drug Schemes. Between January and September 2023, expenditure on liraglutide (Saxenda®) under the Drugs Payment and General Medical Services schemes was €1.8 million.

**December 2023**

**HSE Medicines Management Programme.**